STOCK TITAN

Alpha Tau Medical Ltd - DRTS STOCK NEWS

Welcome to our dedicated page for Alpha Tau Medical news (Ticker: DRTS), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical stock.

Overview

Alpha Tau Medical Ltd (DRTS) is a clinical-stage oncology therapeutics company that focuses on the research, development, and commercialization of innovative radiotherapy solutions for the treatment of solid tumors. Utilizing breakthrough Alpha DaRT technology, the company harnesses the potent and localized effects of alpha particles in cancer treatment. This advanced therapy is rooted in rigorous research and clinical investigations aimed at offering an alternative to conventional radiotherapy, with a focus on targeting tumors while preserving the surrounding healthy tissues.

Technological Innovation

The core technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), employs radioactive sources impregnated with radium-224. When these sources are implanted intratumorally, the radium decays to release short-lived alpha-emitting atoms, which provide a high-energy, localized dose of radiation. The unique properties of alpha particles enable a highly potent and conformal irradiation of solid tumors, minimizing collateral damage to healthy tissue. This methodology sets Alpha Tau apart by addressing treatment challenges in cancers that are otherwise difficult to manage with existing therapies.

Clinical Progress and Research

Alpha Tau Medical has established a broad-based clinical research program with multiple studies across various international locations. Its clinical investigations span several cancer types including cutaneous squamous cell carcinoma, pancreatic, liver, and lung cancers. The company’s clinical trials explore the safety, feasibility, and potential immune-modulating effects of Alpha DaRT. Through rigorous preclinical evaluations and carefully designed clinical studies, the company has demonstrated the potential benefits of delivering localized alpha radiation therapy, such as the observed abscopal effects, which indicate systemic responses even in untreated tumors. These trials underline the company’s commitment to advancing oncologic treatments through collaborative efforts with reputed medical institutions and research centers.

Operational and Business Model

Alpha Tau Medical’s operational model is centered on its advanced R&D capabilities and its ongoing clinical trials aimed at validating Alpha DaRT technology. By collaborating with academic and clinical research institutions, the company continues to refine the technical delivery and therapeutic value of its treatment. Although the financial details remain secondary to its research activities, the company strategically invests in expanding its manufacturing capabilities to support multi-center clinical studies. Such initiatives not only underscore its commitment to quality and compliance with international standards but also build a robust infrastructure for the potential commercialization of the therapy.

Market Position and Significance

Within the highly competitive field of oncology therapeutics, Alpha Tau Medical distinguishes itself by focusing on the localized treatment of solid tumors and by leveraging the distinct characteristics of alpha particle radiation therapy. Its technology is positioned at a unique intersection of innovation and clinical validation, adding a valuable dimension to the array of cancer treatment modalities. The company is part of a broader trend toward personalized and precision medicine, where targeted approaches offer potential benefits to patients with hard-to-treat malignancies. Additionally, Alpha Tau's extensive research collaborations and regulatory communications have helped enhance its credibility and underscore its commitment to scientific excellence.

Competitive Landscape and Industry Insights

In an industry marked by constant innovation, Alpha Tau Medical competes with companies pursuing various advanced radiotherapy and immunotherapy strategies. What sets Alpha Tau apart is its emphasis on the physical properties of alpha particles to deliver a targeted therapeutic effect, thereby offering an alternative mechanism compared to broader-spectrum radiation therapies. The company’s progress in clinical trials and its continuous refinement of the Alpha DaRT delivery system are critical components that bolster its standing amongst its peers. By staying at the cutting edge of clinical research and manufacturing processes, Alpha Tau maintains a rigorously validated approach in its quest to address significant unmet medical needs.

Conclusion

Alpha Tau Medical Ltd represents a pioneering force in the field of oncology therapeutics. With its innovative Alpha DaRT technology, it offers a refined and potent approach to radiotherapy that capitalizes on the unique benefits of alpha-emitting particles. The company’s continued focus on comprehensive clinical evaluations, robust research methodologies, and strategic operational scaling underscores its potential to dramatically influence the future of solid tumor treatment. This detailed overview provides insight into the company’s business model, clinical trial progress, and its considerable impact on the field of cancer therapeutics.

Rhea-AI Summary

Alpha Tau Medical (NASDAQ: DRTS) has received FDA approval for an Investigational Device Exemption (IDE) to begin a pilot study treating recurrent glioblastoma (GBM) patients with their Alpha DaRT® technology. The trial will enroll up to 10 U.S. patients with recurrent GBM who are not candidates for surgery and have previously undergone central nervous system radiation.

The study's primary goal is to assess the feasibility and safety of the treatment, building on promising pre-clinical results. This approval follows the FDA's earlier Breakthrough Device Designation and acceptance into the FDA's Total Product Life Cycle Advisory Program, aimed at accelerating the Alpha DaRT treatment's path to market.

Glioblastoma is described as one of the most complex and treatment-resistant cancers, with an average survival rate of only 8 months, according to the National Brain Tumor Society.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.2%
Tags
-
Rhea-AI Summary

Alpha Tau Medical (NASDAQ: DRTS) reported its full year 2024 financial results and corporate updates. The company's innovative Alpha DaRT cancer therapy showed promising interim results across multiple trials:

Key clinical highlights include high disease control rates in pancreatic cancer trials, and impressive response rates in combination with Keytruda for head and neck cancer treatment. The company received FDA approval for a U.S. pilot study combining Alpha DaRT with first-line chemotherapy for pancreatic cancer patients.

Financial results show:

  • R&D expenses: $27.0M (vs $26.4M in 2023)
  • Net loss: $31.8M or $0.45 per share (vs $29.2M in 2023)
  • Cash position: $62.9M (vs $84.9M in 2023)
The company expects its current cash balance to fund operations for at least two years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
-
Rhea-AI Summary

Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® alpha-radiation cancer therapy, has announced its participation in upcoming investor conferences for March 2025. The company's CFO, Raphi Levy, will be presenting and available for one-on-one investor meetings.

Investors interested in scheduling meetings with Mr. Levy can coordinate through their representatives at Investor Summit Group, Oppenheimer, and Sidoti. The conferences represent an opportunity for investors to learn more about Alpha Tau's innovative cancer treatment technology and business developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
conferences
Rhea-AI Summary

Alpha Tau Medical (NASDAQ: DRTS) has achieved Medical Device Single Audit Program (MDSAP) certification for its Jerusalem manufacturing facility. This certification, established by regulatory authorities from Australia, Brazil, Canada, Japan, and the U.S., enables medical device manufacturers to undergo a single audit for ISO 13485 compliance and standards across these five markets.

The MDSAP certification may accelerate the commercialization timeline in participating countries through a streamlined auditing process. This achievement reflects Alpha Tau's commitment to quality, safety, and regulatory compliance while supporting the global expansion of their Alpha DaRT® alpha-radiation cancer therapy for solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
none
-
Rhea-AI Summary

Alpha Tau Medical (NASDAQ: DRTS) has received FDA approval for an IDE supplement to expand its pilot trial of Alpha DaRT® cancer therapy. The expanded study will now include 30 total patients across two cohorts: patients with locally advanced pancreatic cancer and those with metastatic pancreatic cancer. This represents an increase from the previously announced 12-patient study examining Alpha DaRT combined with first-line chemotherapy in newly diagnosed metastatic pancreatic cancer patients.

The expanded trial will be conducted across up to 10 U.S. clinical trial sites, with each cohort consisting of 15 patients. This expansion follows recently released data showing positive results in disease control and overall survival for pancreatic cancer patients treated with Alpha DaRT.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
-
Rhea-AI Summary

Alpha Tau Medical (NASDAQ: DRTS) announced positive interim data from multiple clinical trials of its Alpha DaRT® cancer therapy. Key highlights include:

In pancreatic cancer trials across Canada and Israel (41 patients), the treatment showed a 100% delivery success rate, 18% objective response rate, and 91% disease control rate. Ad-hoc analyses suggested improved median overall survival compared to historical studies.

In head and neck cancer trials combining Alpha DaRT with pembrolizumab (8 patients), results showed a 75% systemic objective response rate and 37.5% systemic complete response rate, significantly higher than historical benchmarks.

The company received FDA approval for a U.S. pilot study combining Alpha DaRT with first-line chemotherapy in metastatic pancreatic cancer patients, and French approval for a multicenter trial with capecitabine in locally advanced pancreatic cancer.

Additional case studies demonstrated promising results in treating liver metastases, lung cancer, and rectal cancer patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.22%
Tags
Rhea-AI Summary

Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® cancer therapy, announced two significant upcoming events. First, an abstract on pancreatic adenocarcinoma trials will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium (January 23-25, 2025) in San Francisco. The presentation will occur during Poster Session B on January 24.

Additionally, the company will host an R&D Update Day on January 27, 2025, where they will discuss new data from both Israeli and Canadian pancreatic cancer trials, including feasibility, safety, tumor response, and survival metrics. The update will also cover findings from trials combining Alpha DaRT with pembrolizumab for head and neck cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
conferences
-
Rhea-AI Summary

Alpha Tau Medical (Nasdaq: DRTS) announced changes to its Board of Directors, with Maya Netser joining and Meir Jakobsohn stepping down but continuing as an advisor. Netser brings over 25 years of experience as a C-level technology leader, board member, and investor. She is the founder of Quantum Leap VC and previously served as CEO of Cabaret Biotech, where she led the company to a successful acquisition by Kite Pharma and Gilead Sciences.

Netser's appointment comes at a strategic time as Alpha Tau expands into internal organ treatments with its Alpha DaRT® cancer therapy. She holds an LL.B and MBA from Tel Aviv University and is a member of the Israeli National Team of Directors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
management
-
Rhea-AI Summary

Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® alpha-radiation cancer therapy, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Uzi Sofer and CFO Raphi Levy will deliver a corporate overview and update on January 16, 2025, from 9:45 AM to 10:25 AM PT at the Westin St. Francis in San Francisco. The presentation will highlight recent company achievements and upcoming data milestones. Institutional investors can schedule one-on-one meetings with the executives through their J.P. Morgan representatives. A webcast of the presentation will be available on the company's website in the Investor Relations section.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
conferences
Rhea-AI Summary

Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® alpha-radiation cancer therapy, has announced its participation in the upcoming Ladenburg Oncology Innovators & Investors Symposium.

CFO Raphi Levy will represent the company at this virtual event, scheduled for December 12, 2024, from 11:00 AM to 11:25 AM EST. The format will include both a presentation and one-on-one meetings, which can be arranged through Ladenburg representatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences

FAQ

What is the current stock price of Alpha Tau Medical (DRTS)?

The current stock price of Alpha Tau Medical (DRTS) is $2.52 as of April 4, 2025.

What is the market cap of Alpha Tau Medical (DRTS)?

The market cap of Alpha Tau Medical (DRTS) is approximately 165.4M.

What is Alpha DaRT technology?

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is a breakthrough technology that utilizes radium-224 impregnated sources to release alpha particles directly into tumors, thereby delivering a potent and localized dose of radiation.

How does Alpha Tau Medical approach cancer treatment?

The company focuses on using its proprietary alpha radiation technology to treat solid tumors, aiming to maximize tumor irradiation while minimizing damage to surrounding healthy tissues through precise, intratumoral delivery.

What types of cancer are being targeted by Alpha Tau?

Alpha Tau’s clinical programs are evaluating the use of Alpha DaRT in various difficult-to-treat cancers, including cutaneous squamous cell carcinoma, pancreatic, liver, and lung cancers, among others.

How is the efficacy of Alpha DaRT being evaluated?

The efficacy of Alpha DaRT is assessed through rigorous preclinical studies and multiple clinical trials, focusing on safety, feasibility, and therapeutic response, including both local and systemic effects.

What differentiates Alpha Tau from other oncology therapeutics companies?

Alpha Tau distinguishes itself by leveraging the unique properties of alpha particles for localized radiotherapy, which allows for highly potent treatment of tumors with reduced impact on healthy tissues compared to traditional radiotherapy techniques.

What role do clinical trials play in Alpha Tau's strategy?

Clinical trials are central to Alpha Tau’s strategy; they validate the safety and effectiveness of the Alpha DaRT technology while building a foundation of clinical evidence necessary for potential commercialization and regulatory approval.

How does Alpha Tau maintain its industry credibility?

The company builds credibility through extensive collaboration with clinical research institutions, transparent reporting of clinical trial outcomes, and by adhering to rigorous scientific and regulatory standards in its research and development efforts.
Alpha Tau Medical Ltd

Nasdaq:DRTS

DRTS Rankings

DRTS Stock Data

165.39M
56.60M
19.65%
1.89%
0.11%
Biotechnology
Healthcare
Link
Israel
Jerusalem